363 related articles for article (PubMed ID: 37300379)
1. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
Dhanasekaran R; Suzuki H; Lemaitre L; Kubota N; Hoshida Y
Hepatology; 2023 Jun; ():. PubMed ID: 37300379
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures in the management of hepatocellular carcinoma.
Hoshida Y; Moeini A; Alsinet C; Kojima K; Villanueva A
Semin Oncol; 2012 Aug; 39(4):473-85. PubMed ID: 22846864
[TBL] [Abstract][Full Text] [Related]
4. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment.
Wang YF; Yuan SX; Jiang H; Li ZX; Yin HZ; Tan J; Dai ZH; Ge CM; Sun SH; Yang F
Theranostics; 2022; 12(9):4163-4180. PubMed ID: 35673582
[No Abstract] [Full Text] [Related]
5. Are we getting closer to understanding intratumor heterogeneity in hepatocellular carcinoma?
Hammoud GM; Ibdah JA
Hepatobiliary Surg Nutr; 2016 Apr; 5(2):188-90. PubMed ID: 27115014
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
8. Tumor Heterogeneity in Breast Cancer.
Turashvili G; Brogi E
Front Med (Lausanne); 2017; 4():227. PubMed ID: 29276709
[TBL] [Abstract][Full Text] [Related]
9. Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA.
Campani C; Zucman-Rossi J; Nault JC
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765775
[TBL] [Abstract][Full Text] [Related]
10. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Chong DQ; Tan IB; Choo SP; Toh HC
Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
[TBL] [Abstract][Full Text] [Related]
11. Dimensions of hepatocellular carcinoma phenotypic diversity.
Désert R; Nieto N; Musso O
World J Gastroenterol; 2018 Oct; 24(40):4536-4547. PubMed ID: 30386103
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data.
Davis-Marcisak EF; Sherman TD; Orugunta P; Stein-O'Brien GL; Puram SV; Roussos Torres ET; Hopkins AC; Jaffee EM; Favorov AV; Afsari B; Goff LA; Fertig EJ
Cancer Res; 2019 Oct; 79(19):5102-5112. PubMed ID: 31337651
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
15. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.
Kurebayashi Y; Ojima H; Tsujikawa H; Kubota N; Maehara J; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Hepatology; 2018 Sep; 68(3):1025-1041. PubMed ID: 29603348
[TBL] [Abstract][Full Text] [Related]
16. Existing and emerging biomarkers in hepatocellular carcinoma: relevance in staging, determination of minimal residual disease, and monitoring treatment response: a narrative review.
Dominguez DA; Wong P; Melstrom LG
Hepatobiliary Surg Nutr; 2024 Feb; 13(1):39-55. PubMed ID: 38322200
[TBL] [Abstract][Full Text] [Related]
17. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
da Costa JB; Gibb EA; Nykopp TK; Mannas M; Wyatt AW; Black PC
Urol Oncol; 2022 Jul; 40(7):287-294. PubMed ID: 30528886
[TBL] [Abstract][Full Text] [Related]
18. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.
Chen B; Garmire L; Calvisi DF; Chua MS; Kelley RK; Chen X
Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):238-251. PubMed ID: 31900465
[TBL] [Abstract][Full Text] [Related]
19. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates.
Guo C; Tang Y; Yang Z; Li G; Zhang Y
Front Immunol; 2022; 13():958161. PubMed ID: 36032071
[TBL] [Abstract][Full Text] [Related]
20. Implications of genetic heterogeneity in hepatocellular cancer.
Suresh A; Dhanasekaran R
Adv Cancer Res; 2022; 156():103-135. PubMed ID: 35961697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
